Pancreatic Cancer Research

ResearcherOrcidActive in the last 2 years

Keith John Roberts

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1799-9829; OpenAlex author ID A5006929532, A5022175559, A5028938513, A5042543144, A5122836639. Sources: OpenAlex.

Their work

Papers
79 (first author 3, last author 22)
Trials
0
Grants
0
Labs led
3
Collaborators
211
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 7 papers · 2021: 8 papers · 2022: 2 papers · 2023: 18 papers · 2024: 14 papers · 2025: 10 papers · 2026: 14 papers

Papers 50 of 79

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Short-Term Outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta-Analysis of Observational Studies. Co-author DOI 10.1002/wjs.70347↗
  3. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  4. Colonization of bile with gammaproteobacteria is associated with reduced survival after surgery for pancreatic cancer in patients receiving gemcitabine-based a… Last author DOI 10.1016/j.ejso.2026.111396↗
  5. Progression of sarcopenia among patients with pancreatic ductal adenocarcinoma receiving neoadjuvant therapy and the impact of pancreatic enzyme replacement th… Last author DOI 10.1016/j.hbpd.2026.07.004↗
  6. Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis. Last author DOI 10.1016/j.hpb.2025.12.018↗
  7. IGF2BP3-mediated regulation of the RNA isoform and modification landscape in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03933-3↗
  8. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  9. Temporary Mesocaval Shunt: A Surgical Strategy to Facilitate Pancreatic Cancer Resection With Complex Vascular Involvement. Co-author DOI 10.1111/ans.70977↗
  10. Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis of Randomised Contro… Co-author DOI 10.1245/s10434-026-20319-7↗
  11. ASO Author Reflections: It is Time to Define an Optimal Duration of Neoadjuvant Treatment in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20436-3↗
  12. ASO Visual Abstract: Neoadjuvant Chemoradiotherapy versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis… Co-author DOI 10.1245/s10434-026-20533-3↗
  13. Intranetwork variation in neoadjuvant therapy delivery for borderline resectable and locally advanced pancreatic cancer: a UK multicentre cohort study. Co-author DOI 10.1308/rcsann.2026.0023↗
  14. Pancreatic Cancer in the Holobiont and Therapeutic Targets: A Review. Last author DOI 10.3390/jcm15093225↗
  15. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  16. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  17. The impact of FDG-PET/CT on the diagnostic pathway of surgically treated pancreatic ductal adenocarcinoma: the Surg-Panc-UK study. Last author DOI 10.1016/j.hpb.2025.05.003↗
  18. Impact of social deprivation upon the preoperative pathway and early surgical outcomes after pancreatoduodenectomy for PDAC and non-PDAC periampullary cancer i… Co-author DOI 10.1016/j.hpb.2025.07.007↗
  19. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  20. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  21. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  22. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
  23. Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma-A Multicentre Propensity Score Matching Analysis of the Recurrence After Whi… Co-author DOI 10.3390/cancers17071223↗
  24. Root Cause Analysis of Patients with Pancreatic Cancer Who Underwent Imaging Not Resulting in a Cancer Diagnosis in the 18 Months Prior to Diagnosis. Co-author DOI 10.3390/cancers17233770↗
  25. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  26. Interplay in galectin expression predicts patient outcomes in a spatially restricted manner in PDAC. Co-author DOI 10.1016/j.biopha.2024.116283↗
  27. Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2024.01.017↗
  28. Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After W… Co-author DOI 10.1016/j.hpb.2024.04.010↗
  29. Factors associated with favourable pathological tumour response after neoadjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2024.09.002↗
  30. Using Data to Improve Healthcare: A Case Study of Pancreatic Enzyme Replacement in Pancreatic Cancer. Co-author DOI 10.1016/j.soncn.2024.151688↗
  31. Effect of peri-adventitial superior mesenteric artery dissection on margin status during pancreaticoduodenectomy for resectable pancreatic cancer: the DISSECT … Co-author DOI 10.1093/bjsopen/zrae075↗
  32. Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective analysis. Co-author DOI 10.1093/bjsopen/zrae076↗
  33. The microbial composition of pancreatic ductal adenocarcinoma: a systematic review of 16S rRNA gene sequencing. Co-author DOI 10.1097/js9.0000000000001762↗
  34. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  35. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  36. Involvement of the Gut Microbiome in the Local and Systemic Immune Response to Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers16050996↗
  37. Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. Co-author DOI 10.3390/curroncol31100461↗
  38. Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14020135↗
  39. Are physical performance and frailty assessments useful in targeting and improving access to adjuvant therapy in patients undergoing resection for pancreatic c… Last author DOI 10.1007/s00423-023-02828-1↗
  40. Evaluation of post-operative surveillance strategies and surgeon perceptions and beliefs of surveillance for pancreatic ductal adenocarcinoma in the UK. Last author DOI 10.1016/j.hpb.2023.06.007↗
  41. A National Audit of Pancreatic Enzyme Prescribing in Pancreatic Cancer from 2015 to 2023 in England Using OpenSAFELY-TPP. Co-author DOI 10.1016/j.soncn.2023.151439↗
  42. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  43. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study. Co-author DOI 10.1038/s41416-023-02220-2↗
  44. Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study. Co-author DOI 10.1093/bjsopen/zrad053↗
  45. Assessing impact, needs and quality-of-life among informal carers of people with pancreatic cancer, a prospective study: the PAN-CARER study protocol. Co-author DOI 10.1136/bmjopen-2022-068178↗
  46. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade. Co-author DOI 10.1158/2326-6066.cir-22-0121↗
  47. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  48. Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentr… Co-author DOI 10.14701/ahbps.23-042↗
  49. Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A Systematic Review. Last author DOI 10.3390/biomedicines11071983↗
  50. Recent Advances in Pancreatic Ductal Adenocarcinoma: Strategies to Optimise the Perioperative Nutritional Status in Pancreatoduodenectomy Patients. Last author DOI 10.3390/cancers15092466↗

Closest collaborators

The 25 strongest of 211 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nikolaos A. Chatzizacharias · 20 shared papers, 2020–2026 · strength 4.10
  2. Robert Peter Sutcliffe · 15 shared papers, 2018–2026 · strength 3.02
  3. Sarah F. Powell-Brett · 14 shared papers, 2021–2026 · strength 2.95
  4. Rupaly Pandé · 17 shared papers, 2019–2026 · strength 2.94
  5. David Christopher Bartlett · 10 shared papers, 2022–2026 · strength 2.42
  6. S.S. Raza · 8 shared papers, 2024–2026 · strength 2.11
  7. James Michael Halle-Smith · 10 shared papers, 2021–2026 · strength 1.98
  8. Lewis A Hall · 8 shared papers, 2021–2026 · strength 1.77
  9. Shahin Hajibandeh · 6 shared papers, 2023–2026 · strength 1.52
  10. Shahab Hajibandeh · 6 shared papers, 2023–2026 · strength 1.52
  11. Adam Enver Frampton · 9 shared papers, 2021–2026 · strength 1.47
  12. Paul A. H. Moss · 7 shared papers, 2020–2026 · strength 1.23
  13. Hayden Pearce · 6 shared papers, 2020–2026 · strength 1.03
  14. Sanjay Pandanaboyana · 5 shared papers, 2020–2026 · strength 1.00
  15. Samir Pathak · 5 shared papers, 2021–2025 · strength 0.97
  16. Shivan Sivakumar · 4 shared papers, 2023–2026 · strength 0.85
  17. Sandra Margielewska‐Davies · 5 shared papers, 2020–2026 · strength 0.82
  18. Siobhan C. McKay · 4 shared papers, 2021–2025 · strength 0.80
  19. Peter Lawrence Zaki Labib · 4 shared papers, 2023–2026 · strength 0.80
  20. Nabeel Merali · 4 shared papers, 2023–2026 · strength 0.78
  21. Francesca Marcon · 6 shared papers, 2020–2024 · strength 0.78
  22. Wayne D. Croft · 4 shared papers, 2023–2026 · strength 0.71
  23. Bilal A. Al-Sarireh · 5 shared papers, 2021–2025 · strength 0.68
  24. Asif Halimi · 4 shared papers, 2020–2026 · strength 0.64
  25. Charlotte Terry · 2 shared papers, 2026 · strength 0.58

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.